In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.

@article{KretzRommel2007InVT,
  title={In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.},
  author={Anke Kretz-Rommel and Fenghua Qin and Naveen Dakappagari and Ruurd Torensma and Susan J. Faas and Dayang Wu and Katherine S. Bowdish},
  journal={Journal of immunotherapy},
  year={2007},
  volume={30 7},
  pages={715-26}
}
Multiple cancer vaccine trials have been carried out using ex vivo generated autologous dendritic cells (DCs) loaded with tumor antigen before readministration into patients. Though promising, overall immunologic potency and clinical efficacy might be improved with more efficient DC-based therapies that avoid ex vivo manipulations, but are instead based on in vivo targeting of DCs. For initial in vivo proof of concept studies, we evaluated targeting of proteins or peptides to DCs through DC… CONTINUE READING